JAK inhibitors have already been shown to modulate these cytokines in atopic dermatitis trials (81) and by blocking signaling of these cytokines abrocitinib has the potential to decrease Th2 induction, induce Tregs, inhibit IgE class-switching, and inhibit mast cell expansion. Here, IGHE is linked to atopic eczema.